The role and significance of unconventional hydrogen bonds in small molecule recognition by biological receptors of pharmaceutical relevance

Current Pharmaceutical Design

Volumn 13, Issue 34, 2007, Pages 3476-3493

  Tóth, Gergely ^a   Bowers, Simeon G ^a   Truong, Anh P ^a   Probst, Gary ^a  

^a ELAN PHARMACEUTICALS   (United States)

Author keywords

interaction; Blue shifting hydrogen bond; C H F C interaction; C H O interaction; N H interaction; N H F C interaction; O H interaction; O H F C interaction; Structure based drug design; Unconventional hydrogen bond; Weakly polar interaction

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; ACETAZOLAMIDE; ALDEHYDE; AMIDE; BMS 184394; CARBONATE DEHYDRATASE INHIBITOR; CELECOXIB; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDE INHIBITOR; DONEPEZIL; DOPAMINE 2 RECEPTOR; FLUOROPHENYLALANINE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HUPERZINE A; HUPERZINE B; PHENYLALANINE DERIVATIVE; PROTEIN INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RECEPTOR BLOCKING AGENT; RETINOIC ACID RECEPTOR GAMMA; RETINOIC ACID RECEPTOR GAMMA ANTAGONIST; SR 11254; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; VALDECOXIB;

AB INITIO CALCULATION; ALTITUDE DISEASE; ALZHEIMER DISEASE; BINDING AFFINITY; COMPLEX FORMATION; CYSTINURIA; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME INHIBITION; EPILEPSY; GLAUCOMA; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; HYPERTENSION; LIGAND BINDING; MOLECULAR INTERACTION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; COMPUTER-AIDED DESIGN; DRUG DESIGN; ENZYMES; HUMANS; HYDROGEN BONDING; IMAGING, THREE-DIMENSIONAL; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 36949004094     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782794284     Document Type: Review

References (95)

1. Burley S, Petsko GA. Weakly polar interactions in proteins. Adv Protein Chem 1988; 39: 125-89.
2. Steiner T, Koellner G. Hydrogen bonds with pi-acceptors in proteins: frequencies and role in stabilizing local 3D structures. J Mol Biol 2001; 305: 535-57.
3. Toth G, Watts C, Murphy RF, Lovas S. Significance of aromatic-backbone amide interactions in protein structure. Proteins 2001; 43: 373-81.
4. Desiraju G. C-H.O and other weak hydrogen bonds. From crystal engineering to virtual screening. Chem Commun 2005; 24: 2995-3001.
5. Meyer A, Castellano RY, Diederich F. Interactions with aromatic rings in chemical and biological recognition. Angewandte Chemie 2003; 42: 1210-50.
6. Zarrinpar A, Lim WA. Converging on proline: The mechanism of WW domain peptide recognition. Nat Struct Biol 2000; 7: 611-3.
7. Jiang L, Lai L. CH.O hydrogen bonds at protein-protein interfaces. J Biol Chem 2002; 277: 37732-40.
8. Pierce A, Sandretto KL, Bemis GW. Kinase inhibitors and the case for CH.O hydrogen bonds in protein-ligand binding. Proteins 2002; 49: 567-76.
9. Cotesta S, Stahl M. The environment of amide groups in protein-ligand complexes: H-bonds and beyond. J Mol Model 2006; 12: 436-44.
10. Hobza P, Havlas Z. Blue-shifting hydrogen bonds. Chem Rev 2000; 100: 4253-64.
11. Nishio M. Weak hydrogen bonds. Encylopedia of SupraMolecular Chemistry 2004; 1576-86.
12. Burley S, Petsko GA. Aromatic-aromatic interaction: A mechanism of protein structure stabilization. Science 1985; 229: 23-8.
13. Grover J, Walters EA, Hui ET. Dissocation energies of the benzene dimer and dimer cation. J Phys Chem 1987; 91: 3233-7.
14. Hobza P, Schlag EW. Potential energy surface for the benzene dimer. Results of ab Initio CCSD(T) calculations show two nearly isoenergetic structures: T-Shaped and parallel-displaced. J Phys Chem 1996; 100: 18790-4.
15. Jaffe RL, Smith GD. A quantum chemistry study of benzene dimer. J Phys Chem 1996; 165: 2780-8.
16. (a) Tsuzuki S. Interactions with Aromatic Rings. Struc. Bond. 2005; 115:149-93.
17. (b) Lee EL, Hong BH, Lee JY, Kim JC, Kim D, Kim Y, et al. Substituent effect on the edge-to-face aromatic interactions. J Am Chem Soc 2005; 127: 4530-7.
18. Tsuzuki S, Honda K, Uchimaru T, Mikami M. High-level ab initio computations of structures and interaction energies of naphthalene dimers: Origin of attraction and its directionality. J Chem Phys 2004; 120: 647-59.
19. Tsuzuki S, Honda K, Azumi S. Model chemistry calculations of thiophene dimer interactions: Origin of pi-stacking. J Am Chem Soc 2002; 124: 12200-9.
20. Park H, Lee S. Ab initio investigations of the pyrrole dimer: A direct observation of the pi-facial hydrogen bond. Chem Phys Lett 1999; 301: 487-92.
21. Pejov L. A gradient-corrected density functional study of indole self-association through N-H.pi hydrogen bonding. Chem Phys Lett 2001; 339: 269-78.
22. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E, et al. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J Med Chem 2002; 45: 2994-3008.
23. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739-46.
24. Cardozo MG, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992; 35: 584-9.
25. Cardozo MG, Kawai T, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. Conformational analyses and Molecular-shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992; 35: 590-601.
26. Kryger G, Silman I, Sussman. Structure of acetylcholinesterase complexed with E2020 (Aricept): Implications for the design of new anti-Alzheimer drugs. Structure 1999; 7: 297-307.
27. Kawakami Y, Inoue A, Kawai T, Wakita M, Sugimoto H, Hopfinger AJ, The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg Med Chem 1996; 4: 1429-46.
28. Soskic V, Joksimovic J Bioisosteric approach in the design of new dopaminergic/serotonergic ligands. Curr Med Chem 1998; 5: 493-512.
29. Bolognese A, Correale G, Manfra M, Lavecchia A, Mazzoni O, Novellino E, et al. Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity. J Med Chem 2004; 47: 849-58.
30. Diurno MV, Mazzoni O, Correale G, Gomez Monterrey I, Calignano A, La Rana G, et al, Synthesis and structure-activity relationships of 2-(substituted phenyl)-3-[3-(N,N-dimethylamino)propyl]-1,3-thiazolidin- 4-ones acting as H1-histamine antagonists. Farmaco 1999; 54: 579-93.
31. Diurno MV, Mazzoni O, Piscopo E, Calignano A, Giordano F, Bolognese A. Synthesis and antihistaminic activity of some thiazolidin-4-ones. J Med Chem 1992; 35: 2910-2.
32. Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib. Bioorg. Med Chem Lett 2006; 16: 437-42.
33. Kim CY, Chang JS, Doyon JB, Baird TT, Fierke CA, Jain A, et al. Contribution of fluorine to protein-ligand affinity in the binding of fluoroaromatic inhibitors to carbonic anhydrase II. J Am Chem Soc 2000; 122: 12125-34.
34. Doyon JB, Jain A. The pattern of fluorine substitution affects binding affinity in a small library of fluoroaromatic inhibitors for carbonic anhydrase. Org Lett 1999; 1: 183-5.
35. Doyon JB, Hansen EA, Kim CY, Chang JS, Christianson DW, Madder RD, et al. Linear free energy relationships implicate three modes of binding for fluoroaromatic inhibitors to a mutant of carbonic anhydrase II. Org Lett 2000; 2: 2557-8.
36. Fujita T, Nose T, Matsushima A, Okada K, Asai D, Yamauchi Y, et al. Synthesis of a complete set of 1-difluorophenylines, 1-(F2)Phe, as Molecular explorers for the CH/pi interaction between peptide ligand and receptor. Tetrahedron Lett 2000; 41: 923-7.
37. Nishio MH, Umezawa Y. The CH/p interaction, Wiley-VCH: New York 1998.
38. Tsuzuki S, Honda K,Uchimaru T, Mikami M, Tanabe K. The magnitude of the CH/interaction between benzene and some model hydrocarbons. J Am Chem Soc 2000; 122: 3746-53.
39. Tsuzuki S, Honda K, Uchimaru T, Mikami M, Tanabe K. The interaction of benzene with chloro- and fluoromethanes: Effects of halogenation on CH/ pi interaction. J Phys Chem A 2002; 106: 4423-8.
40. van der Veken BJ, Herrebout WA, Szostak R, Shchepkin DN, Havlas Z, Hobza P. The nature of improper, blue-shifting hydrogen bonding verified experimentally. J Am Chem Soc 2001; 123: 12290-3.
41. Toth G, Murphy RF, Lovas S. Stabilization of local structures by p-CH and aromatic-backbone amide interactions involving prolyl and aromatic residues. Protein Eng 2001; 14: 543-7.
42. Toth G, Kover KE, Murphy RF, Lovas S. Aromatic-backbone interactions in α-helices. J Phys Chem B 2004; 108: 9287-96.
43. Nishio M. CH/p hydrogen bonds in crystals. CrystEngComm 2004; 6:130-58.
44. Nishio M, Umezawas, Y, Hiroto M, Takeuchi Y. The CH/p interaction: significance in Molecular recognition. Tetrahedron 1995; 51: 8665-701.
45. Nakagawa Y, Irie K, Yanagita RC, Ohigashi H, Tsuda K. Indolactam-V is involved in the CH/pi interaction with Pro-11 of the PKCdelta C1B domain: Application for the structural optimization of the PKCdelta ligand. J Am Chem Soc 2005; 127: 5746-7.
46. Irie K, Nakagawa Y, Ohigashi H. Toward the development of new medicinal leads with selectivity for protein kinase C isozymes. Chem Rec 2005; 5: 185-95.
47. Wang S, Liu M, Lewin NE, Lorenzo PS, Bhattacharrya D, Qiao L, et al. Probing the binding of indolactam-V to protein kinase C through site-directed mutagenesis and computational docking simulations. J Med Chem 1999; 42: 3436-46.
48. Wantanabe T, Suzuki T, Umezama Y, Takeuchi T, Otsuka M. Structure-activity relationship and rational design of 3,4-dephostatin derivatives as protein tyrosine phosphatase inhibitors. Tetrahedron 2000; 56: 741-52.
49. Schoepfer J, Gay B, Caravatti G, Garcia-Echeverria C, Fretz H, Rahuel J, et al. Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain. Bioorg Med Chem Lett 1998; 8: 2865-70.
50. Schoepfer J, Fretz H, Gay B, Furet P, Garcia-Echevenia C, End N, et al. Highly potent inhibitors of the Grb2-SH2 domain. Bioorg Med Chem Lett 1999; 9: 221-6.
51. Umezawa Y, Nishio M, CH/pi interactions as demonstrated in the crystal structure of guanine-nucleodde binding proteins, Src hoMology-2 domains and human growth hormone in complex with their specific ligands. Bioorg Med Chem 1998; 6: 493-504.
52. Garcia-Echeverria C, Furet P, Gay B, Fretz H, Rahuel J, Schoepfer J, et al. Potent antagonists of the SH2 domain of Grb2: Optimization of the X+1 position of 3-amino-Z-Tyr(PO3H2)-X+1-Asn-NH2. J Med Chem 1998; 41: 1741-4.
53. Momose I, Umezawa Y, Hirosawa, S, Iinuma, H, Ikeda D. Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of marnmalian 20S proteasome. Bioorg Med Chem Lett 2005; 15: 1867-71.
54. Groll M, Ditzel L, Lowe J, Tomisugi Y, Tanaka K, Yasuoka N, et al. Structure determination of the constitutive 20S proteasome from bovine liver at 2.75 Å resolution. J Biochem (Tokyo) 2002; 131: 171-3.
55. Umezawa Y. Nishio M. CH/pi hydrogen bonds as evidenced in the substrate specificity of acetylcholine esterase. Biopolymers 2005; 79: 248-58.
56. Berley S, Petsko GA. Amino-aromatic interactions in proteins. FEBS Lett 1986; 203: 139-43.
57. Dougherty DA. Cation-pi interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp. Science 1996; 271: 163-8.
58. Zacharia N, Dougherty DA. Cation-pi interactions in ligand recognition and catalysis. Trends Pharmacol Sci 2002; 23: 281.
59. Suzuki S, Green P, Bumgarner RE, Dasgupta S, Goddard WA, Blake GA. Benzene forms hydrogen bonds with water. Science 1992; 275: 942-5.
60. Rodham D, Suzuki SA, Suenrarn RF, Lovas FJ, Dasgapta S, Goddard WA, et al. Hydrogen bonding in the benzene-ammonia dimer. Nature 1993; 362: 735-7.
61. Tsuzuki S, Honda K, Uchimaru T, Mikami M, Tanabe K. Origin of the attraction and directionality of the NH/p interaction: Comparison with OH/and CH/p interactions. J Am Chem Soc 2000; 122: 11450-8.
62. Toth G, Murphy RF, Lovas S. Investigation of aromatic-backbone amide interactions in the model peptide acetyl-Phe-Gly-Gly-N-methyl amide using Molecular dynamics simulations and protein database search. J Am Chem Soc 2001; 123: 11782-90.
63. Ming T, Cascieri MA, Yu H. Bansal A, Swain C, Strader CD. Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP96345. Nature 1993; 362: 350-3.
64. Foloppe N, Fisher LM, Francis G, Howes R, Kierstan P, Potter A. Identification of a buried pocket for potent and selective inhibition of Chk1: Prediction and verification. Bioorg Med Chem 2006; 14: 1792-804.
65. Oku K, Watanabe H, Kubota M, Fukuda S, Kurimoto M, Tsujisaka Y, et al. NMR and quantum chemical study on the OH.pi and CH.O interactions between trehalose and unsaturated fatty acids: Implication for the mechanism of antioxidant function of trehalose. J Am Chem Soc 2003; 125: 12739-49.
66. Madhan B, Thanikaivelan P, Subramanian V, Raghava Rao J, Unni Nair B, Ramasami T. Molecular mechanics and dynamics studies on the interaction of gallic acid with collagen-like peptides. Chem Phys Lett 2001; 346: 334-40.
67. Gu Y, Kar T, Scheiner S. Fundamental Properties of the CH.O Interaction: Is it a True Hydrogen Bond? J Am Chem Soc 1999; 121: 9411-22.
68. Derewenda ZS, Derewenda U, Kobos PM. (His)C epsilon-H.O=C < hydrogen bond in the active sites of serine hydrolases. J Mol Biol 1994; 241: 83-93.
69. Scheiner A, Kar T, Gu Y. Strength of the CaH.O hydrogen bond of amino acid residues. J Biol Chem 2001; 276: 9832-7.
70. Fabioloa G, Krishnaswamy S, Nagarajan V, Pattabhi V. C-H.O hydrogen bonds in b sheets. Acts. Crystallogr D Biol Crystallogr 1997; 53: 316-20.
71. Chakrabarti P, Chakrabarti S. C-H.O hydrogne bond involving proline residues in a-helices. J Mol Biol 1998; 284: 867-73.
72. Manikandan K, Ramakumar S. The occurrence of C-H.O hydrogne bonds in alpha-helices and helix termini in globular proteins. Proteins 2004; 56: 768-7681.
73. Klaholz B, Moras D. C-H.O hydrogen bonds in the nuclear receptor RARgamma - a potential tool for drug selectivity. Structure 2002; 10: 1197-204.
74. Klaholz BP, Mitschler A, Moras D. Structural basis for isotype selectivity of the human retinoic acid nuclear receptor. J Mol Biol 2000; 302: 155-70.
75. Engh RA, Brandstetter H, Sucher G, Eichinger A, Baumann U, Bode W, et al. Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: Implications for drug design. Structure 1996; 4: 1353-62.
76. Brandstetter H, Turk D, Hoeffken HW, Grosse D, Sturzebecher J, Martin PD, et al. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. J Mol Biol 1992; 226: 1085-99.
77. Pierce AC, ter Haar E, Binch HM, Kay DP, Patel SR, LiP, CH.O and CH.N hydrogen, bonds in ligand design: A novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor. J Med Chem 2005; 48: 1278-81.
78. Smart B. Fluorine substituent effects (on bioactivity). J Fluor Chem 2001; 109: 3-11.
79. Reed A, Curtiss LA. InterMolecular interactions from a natural bond orbital, donor-acceptor viewpoint. Chem Rev 1988; 88: 899-926.
80. Dunitz J, Taylor R. Organic fluorine hardly ever accepts hydrogen bonds. Chem Eur J 1996; 3: 89-98.
81. Dunitz J, Taylor R. Organic fluorine: Odd man out. ChemBioChem 2004; 5: 614-21.
82. Alkorta, I, Rozas I, Elguero I An attractive interaction betwen the pi-cloud of C6F6 and eletron donor atoms. J Org Chem 1997; 62: 4687-91.
83. Alkorta I, Rozas I, Elguero J Interaction of Anions with Perfluoro Aromatic Compounds. J Am Chem Soc 2002; 124: 8593-8.
84. Alkorta I, Rozes I, Elguero J. A theoretical and experimental study of the interaction of C6F6 with electron donors. Struct Chem 2001; 12: 459-64.
85. Herdewijn P, Pauwels R, Baba M, Balzarini J, De Clercq E. Synthesis and anti-HIV activity of various 2′- and 3′-substituted 2′,3′-dideoxyadenosines: A structure-activity analysis. J Med Chem 1987; 30: 2131-7.
86. Mu L, Sarafianos SG, Nicklaus MC, Russ P, Siddiqui MA, Ford H, et al. Interactiom of conformationally biased north and south 2′-fluoro-2′, 3′-dideoxynucleoside 5′-triphosphates with the active site of HIV-1 reverse transcriptase. Biochemistry 2000; 39: 11205-15.
87. Mattos C, Rasmussen B, Ding X, Petsko GA, Ringe D. Analogous inhibitors of elastase do not always bind analogously. Nat Struct Biol 1994; 1: 55-8.
88. Dunitz JD, Taylor R. Organic fluorine hardly ever accepts hydrogen bonds. Chem Eur J 1997; 3: 89-98.
89. Parlow JJ, Kurumbail RG, Stegeman RA, Stevens AM, Stallings WC, South MS. Synthesis and X-ray crystal structures of substituted fluorobenzene and benzoquinone inhibitors of the tissue factor VIIa complex. Bioorg Med Chem Lett 2003; 13: 3721-5.
90. Parlow JJ, Stevens AM, Stegeman RA, Stallings WC, Kurumbail RG, South MS. Synthesis and crystal structures of substituted benzenes and benzoquinones as tissue factor VIIa inhibitors. J Med Chem 2003; 46: 4297-312.
91. Bohm H.J, Banner D, Bendels S, Kansy M, Kuhn B, Muller K, et al. Fluorine in medicinal chemistry. Chembiochem 2004; 5: 637-43.
92. Brady K, Wei AZ, Ringe D, Abeles RH. Structure of chymotrypsin-trifluoromethyl ketone inhibitor complexes: Comparison of slowly and rapidly equilibrating inhibitors. Biochemistry 1990; 29: 7600-7.
93. Street IP, Armstrong CR, Withers SG. Hydrogen bonding and specificity. Fluorodeoxy sugars as probes of hydrogen bonding in the glycogen phosphorylase-glucose complex. Biochemistry 1986; 25: 6021-7.
94. Martin JL, Johnson LN, Withers SG. Comparison of the binding of glucose and glucose 1-phosphate derivatives to T-state glycogen phosphorylase b. Biochemistry 1990; 29: 10745-57.
95. Razgulin AV, Mecozzi S. Binding properties of aromatic carbon-bound fluorine. J Med Chem 2006; 49: 7902-6.